<DOC>
	<DOCNO>NCT00886587</DOCNO>
	<brief_summary>The purpose study evaluate safety investigational study product see well work relieve sign symptom child mild moderate Atopic Dermatitis ( AD ) , also know eczema , comparison similar market product . This study do see safe investigational new study product well work treat AD child , make AD visually well , reduce amount itch .</brief_summary>
	<brief_title>To Evaluate Safety Efficacy New Device Management Mild Moderate Atopic Dermatitis Children</brief_title>
	<detailed_description>This multi-center , double-blind , randomize , active-controlled trial child 2 12 year age mild moderate AD . A sufficient number subject screen ensure approximately 80 subject randomize , yield 70 complete subject . Subjects randomize one two treatment group : J &amp; J Device AtopiclairÂ® . All subject return clinical site clinical assessment baseline ( Day 1 ) Days 3 , 8 , 15 , 22 , 29 43 initial investigational product application . The investigational product use topically duration study .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<criteria>Postmenarchal female subject must negative urine pregnancy test Willing provide write informed consent/assent Diagnosed mild moderate Atopic Dermatitis ( AD ) Willing stop moisturizers and/or skin barrier cream emulsion treatment AD condition test period replace investigational product assign trial Willing replace body wash and/or soap one provide trial Severe AD determine RajkaLangeland Severity Index AD require systemic , superpotent ( Class I ) potent ( Class II III ) topical corticosteroid ( See Topical Corticosteroid Potency Chart Section 5.6 ) . If subject require medication rescue therapy study , subject discontinue trial History allergy hypersensitivity ingredient test device , nut nut oil Cutaneous systemic viral ( include HIV AIDS ) , mycotic bacterial disease require topical systemic therapy Diabetes mellitus control diet alone ( i.e. , require systemic medication control )</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>eczema</keyword>
</DOC>